Adenomyosis lowers clinical pregnancy and live birth rates and raises miscarriage risk in IVF patients, but the size of that effect depends heavily on disease severity and which treatment path you take before transfer. A 2024 systematic review and meta-analysis found a significant reduction in clinical pregnancy and live birth rates compared with women without adenomyosis, alongside a substantially increased miscarriage rate. That is a meaningful gap, but it is not a verdict against IVF. It is a signal that your protocol needs to account for what your imaging shows.

The strongest evidence points to three actions that consistently move the needle:

Get your disease classified properly, using MUSA-based imaging criteria rather than a vague “adenomyosis present/absent” note, since direct ultrasound markers carry a far worse prognosis than indirect ones.
Discuss a freeze-all cycle with GnRHa down-regulation, typically 2 to 4 months, which multiple reviews link to improved uterine receptivity before frozen embryo transfer.
Ask whether surgery fits your case, since focal or diffuse disease, lesion size, and your reproductive timeline all change whether a procedural option makes sense.

Adenomyosis does not determine an individual outcome by itself. Disease severity, imaging findings, age, embryo factors, and the treatment plan can all influence prognosis.

Key Takeaways

Adenomyosis lowers average IVF success rates, but disease severity on imaging, not the diagnosis alone, determines your realistic individual prognosis.

Point	Details
Effect size is real but variable	Meta-analysis data shows lower clinical pregnancy and live birth rates, with results varying by severity.
Imaging classification changes everything	Direct MUSA markers signal a higher-risk phenotype with sharply lower live birth odds than indirect markers alone.
Freeze-all plus GnRHa is the leading strategy	Deferred FET after 2 to 4 months of down-regulation is the most evidence-supported approach for improving receptivity.
Surgery fits a narrow group	Focal, well-defined lesions may suit surgical options; diffuse disease generally favors medical management instead.
Ask for specifics, not labels	Request your exact marker type, lesion pattern, and suppression rationale before accepting a standard protocol.
Life IVF Center builds protocols around your imaging	The Precision IVF® approach reviews MUSA findings before recommending suppression, transfer timing, or surgical evaluation.

What Adenomyosis Is and How It Affects Fertility
Diagnosing Adenomyosis for IVF Planning
What the Evidence Shows About IVF Outcomes With Adenomyosis
Treatment Options Before and During IVF With Adenomyosis
Building Your IVF Protocol Discussion Around Adenomyosis
Questions to Ask About Your Personal IVF Prognosis
Where the Evidence Falls Short
How a Specialized Clinic Approaches Adenomyosis in IVF Planning
A Manageable Factor, Not a Verdict
Getting Evidence-Based Adenomyosis Care Before Your Next IVF Cycle
Frequently Asked Questions
Sources

What Adenomyosis Is and How It Affects Fertility

Adenomyosis happens when endometrial tissue, the lining that normally sheds each month, grows into the muscular wall of the uterus instead of staying confined to the cavity. The result is a uterus that can look enlarged, feel tender, and bleed heavily, though a meaningful share of cases are picked up incidentally during fertility workups with no symptoms at all. It’s a structural condition, but its consequences for fertility are mostly biochemical.

The tissue misplaced in the myometrium behaves like a low-grade irritant. It triggers local inflammation, and that inflammation appears to be the hinge connecting adenomyosis to fertility issues years before a diagnosis ever gets made. Inflamed uterine tissue produces excess prostaglandins and cytokines, which can drive abnormal uterine contractility, the kind of contraction pattern that can physically interfere with an embryo trying to implant.

Beyond mechanics, there’s a molecular story. Research on adenomyosis-associated infertility points to disrupted signaling in the pathway involving LIF and STAT3, two components the endometrium relies on to prepare for decidualization, the transformation the lining undergoes to support an embryo. When that signaling is impaired, the endometrium can also develop a form of progesterone resistance, meaning it doesn’t respond normally to the hormone that should be softening and readying it for pregnancy.

Put simply, the pathway runs: misplaced endometrial tissue creates local inflammation, inflammation disrupts receptivity signaling and increases contractility, and the combination raises the odds of implantation failure or early pregnancy loss. None of this means the uterus is permanently inhospitable. It means the uterine environment at the moment of transfer needs deliberate management, which is exactly where modern IVF protocols for adenomyosis focus their attention.

Diagnosing Adenomyosis for IVF Planning

Two imaging tools do almost all the diagnostic work: transvaginal ultrasound and MRI. TVUS is the recommended first-line test in current obstetrics and gynecology guidelines, largely because it’s accessible, inexpensive, and highly sensitive in experienced hands. MRI offers better tissue contrast and is useful when ultrasound findings are ambiguous or when a patient has a body habitus or fibroid burden that limits ultrasound visibility, but it costs more and isn’t necessary for most patients.

What actually matters for your prognosis isn’t just whether adenomyosis is present. It’s which specific features show up on the scan. The MUSA criteria (Morphological Uterus Sonographic Assessment) give radiologists and reproductive endocrinologists a standardized vocabulary for describing adenomyosis, and they separate findings into two categories with very different clinical weight.

Marker type	Examples	Clinical significance
Direct markers	Myometrial cysts, hyperechogenic islands, echogenic subendometrial lines/buds	Associated with a high-risk phenotype and substantially lower live birth rates
Indirect markers	Junctional zone irregularity, asymmetric myometrial wall thickening, fan-shaped shadowing	Suggest adenomyosis-related change but carry a less severe prognostic signal

A 2026 prospective cohort study following ART patients found that those with direct markers had a substantially reduced chance of live birth and a markedly higher pregnancy loss risk compared with patients without those features, even after adjusting for age and other confounders. That’s a striking gap between two patients who might otherwise both carry the same “adenomyosis” label on their chart.

Ask your clinic specifically whether your report notes direct or indirect markers, not just a general adenomyosis diagnosis.
Request the estimated lesion location (anterior, posterior, diffuse) since it affects both surgical feasibility and transfer planning.
If your only imaging was a routine ultrasound during an unrelated visit, ask whether a dedicated MUSA-based scan would sharpen your prognosis.

Pro Tip: Bring your actual ultrasound report, not just the summary letter, to your fertility consultation. The radiologist’s specific language about cysts, junctional zone thickness, or hyperechogenic islands carries more prognostic weight than a one-line “adenomyosis noted” comment.

What the Evidence Shows About IVF Outcomes With Adenomyosis

The research on adenomyosis ivf outcomes has grown substantially over the last several years, and a clear pattern has emerged across meta-analyses, cohort studies, and mechanistic reviews: adenomyosis lowers the odds of a live birth, but the magnitude of that effect varies with how the disease is defined and measured.

The 2024 meta-analysis pooling multiple IVF/ICSI studies reported lower clinical pregnancy and live birth rates in adenomyosis patients compared with matched controls, with miscarriage rates nearly twice as high. Those numbers represent averages across a genuinely mixed patient population, women with mild indirect changes sit in the same pooled estimate as women with extensive diffuse disease. This is exactly why severity-stratified data matters so much.

That’s where the prospective cohort data adds precision the meta-analyses can’t. The 2026 cohort study on direct adenomyosis features found that patients with direct ultrasound markers represented a distinct, higher-risk reproductive phenotype, with notably lower live birth odds and markedly higher pregnancy loss rates compared with patients without those markers. Patients with indirect-only findings tracked much closer to non-adenomyosis controls. This distinction reframes the clinical conversation: “adenomyosis” isn’t one prognosis, it’s a spectrum, and where you fall on it should shape how aggressively your team intervenes before transfer.

A separate prospective observational study looking specifically at donor oocyte transfers found decreased pregnancy rates and elevated miscarriage even when egg quality was effectively controlled for, since donor eggs come from young, screened donors. That detail matters. It tells us the uterine environment itself, not just the embryos being transferred, drives much of the adverse outcome pattern in adenomyosis.

Outcome measured	Adenomyosis patients	Comparison group	Source
Clinical pregnancy rate	substantially lower	Non-adenomyosis IVF patients	Meta-analysis, 2024
Live birth rate	markedly lower	Non-adenomyosis IVF patients	Meta-analysis, 2024
Miscarriage rate	nearly twice as high	Non-adenomyosis IVF patients	Meta-analysis, 2024
Live birth odds, direct markers	a significant reduction	Adenomyosis without direct markers	Prospective cohort study
Pregnancy loss, direct markers	Nearly 4 times higher	Adenomyosis without direct markers	Prospective cohort study

None of this evidence is beyond criticism. Study populations differ in how adenomyosis was diagnosed (some rely on symptoms and clinical exam, others strictly on imaging with MUSA criteria), and outcomes differ between fresh and frozen transfer protocols in ways that aren’t always separated out in pooled analyses. Age, BMI, and coexisting endometriosis, which frequently overlaps with adenomyosis, also confound the picture. A literature review in PMC reached the same directional conclusion, lower pregnancy and live birth rates, higher miscarriage, while explicitly calling for more individualized management rather than one-size-fits-all counseling. The honest summary: the direction of the effect is well established, but the exact size of your personal risk depends on factors a pooled percentage can’t capture.

Treatment Options Before and During IVF With Adenomyosis

Managing adenomyosis during IVF usually comes down to a choice between suppressing the disease medically before transfer, adjusting the transfer strategy itself, or, in select cases, addressing the lesion surgically. None of these options is universal. What fits depends on disease pattern, prior treatment history, and how much time a patient has before age or ovarian reserve becomes the more pressing constraint.

GnRHa down-regulation is the most studied medical approach. It involves suppressing estrogen production for a defined stretch, typically 2 to 4 months, before attempting embryo transfer. The rationale is straightforward: adenomyotic tissue is estrogen-sensitive, so creating a temporary low-estrogen state can quiet the inflammatory activity driving poor receptivity. Current guideline recommendations support this approach for selected patients, and mechanistic reviews describe how prolonged suppression can help restore a more normal uterine environment ahead of transfer. The evidence isn’t uniformly strong across every study design, but the direction is consistent enough that it’s now a standard discussion point in adenomyosis-specific IVF counseling.

Freeze-all with deferred frozen embryo transfer (FET) frequently pairs with GnRHa suppression, and for good reason. A fresh transfer happens on a fixed timeline dictated by the stimulation cycle, leaving no room to first calm an inflamed uterine environment. Freezing the embryos and deferring transfer buys time for suppression therapy to take effect, then allows the transfer to happen in a controlled, medicated cycle where the endometrium can be prepared deliberately rather than reactively.

LNG-IUD and progestin-based approaches appear in some treatment protocols, generally aimed at reducing adenomyosis-related inflammation and bleeding before a patient proceeds to IVF. The data here is thinner than for GnRHa and freeze-all strategies, and outcomes vary across the reviews that have looked at it, which means it tends to come up as a secondary consideration rather than a first-line recommendation.

Surgical options exist for a smaller subset of patients, generally those with focal, well-defined lesions rather than diffuse disease throughout the myometrium. These include adenomyomectomy (surgical excision of the adenomyotic tissue), focal excision, high-intensity focused ultrasound (HIFU), and uterine artery embolization. Each carries trade-offs:

Adenomyomectomy can reduce lesion burden but carries a real risk of compromising uterine wall integrity, which raises concerns about uterine rupture in a subsequent pregnancy.
HIFU is less invasive but has a shorter track record specifically in fertility-preserving contexts.
Uterine artery embolization is generally not recommended for women who still want to conceive, given its effects on uterine blood supply.
Diffuse disease responds poorly to focal surgical approaches, since there’s no single lesion to remove.

Medical suppression followed by frozen embryo transfer is one strategy clinicians may discuss, while surgery is generally reserved for selected cases. The appropriate approach depends on disease pattern, symptoms, reproductive goals, ovarian reserve, and prior treatment history.

Building Your IVF Protocol Discussion Around Adenomyosis

Turning this evidence into an actual clinic conversation means walking in with specific questions rather than a general concern about your diagnosis. A useful checklist to bring to your reproductive endocrinologist includes:

Ask for the specific MUSA classification on your imaging report, direct markers, indirect markers, or both.
Ask whether a freeze-all cycle is being recommended, and if not, why a fresh transfer is considered appropriate for your case.
Ask what duration of GnRHa suppression, if any, your clinic recommends and how that decision was reached.
Ask whether blastocyst-stage transfer is planned, since many adenomyosis protocols favor blastocyst over cleavage-stage embryos to allow better synchronization with a prepared endometrium.
Ask what monitoring will track whether suppression therapy is working before you proceed to transfer.

How your clinic answers the “medical suppression versus surgery” question should hinge largely on whether your disease is diffuse or focal. Diffuse disease, spread broadly through the myometrium, generally favors medical management since there’s no isolated lesion a surgeon can remove without risking significant uterine damage. Focal disease with a clearly bordered lesion opens the door to a surgical conversation, particularly if medical suppression alone hasn’t resolved symptoms or prior transfer attempts have failed.

Pro Tip: If your clinic recommends a specific GnRHa duration, ask what marker they’re using to confirm it’s working, whether that’s symptom improvement, a repeat ultrasound, or hormone levels, rather than just proceeding on a fixed calendar.

Suppression can add time before transfer. When recommended, the purpose is to manage the uterine environment before a later transfer, but the potential benefit and timing should be individualized.

Questions to Ask About Your Personal IVF Prognosis

Generic statistics only tell you so much. Your actual prognosis depends on specifics that only your imaging and history can supply, so bring these questions to your consultation:

What does my ultrasound or MRI report say specifically, direct markers, indirect markers, lesion size, and location?
Is my adenomyosis diffuse or focal, and does that change which treatment path makes sense for me?
Given my imaging findings, what live birth probability range would you estimate for my case?
Would a repeat scan with 3D ultrasound or MRI meaningfully change your recommendation?
If I’ve already had a failed cycle, was adenomyosis specifically accounted for in that protocol?

If your clinician confirms direct markers on your scan, treat that as a meaningful data point rather than something to dismiss. It means your case sits in the higher-risk category the 2026 cohort data describes, and it justifies a more assertive suppression and monitoring plan rather than a standard protocol. A second opinion or specialized imaging is reasonable any time your current report feels vague or when a prior cycle failed without a clear explanation.

Where the Evidence Falls Short

The research on adenomyosis and IVF has real gaps worth knowing about. Studies use inconsistent diagnostic criteria, some rely on symptoms, others on ultrasound, others on MRI, which makes it hard to compare results cleanly across the literature or trust pooled estimates as precise numbers rather than general directional signals.

Randomized controlled trials comparing specific pretreatment protocols (extended versus standard GnRHa duration, LNG-IUD versus no pretreatment, fresh versus FET) with live birth as the primary endpoint remain scarce.
Optimal suppression duration by disease severity hasn’t been established through controlled trials.
Adjunctive anti-inflammatory strategies, including low-dose aspirin in some protocols, lack robust trial data specific to adenomyosis populations, so their role remains a reasonable but unproven adjunct rather than an established standard.
Long-term obstetric outcomes for adenomyosis patients who conceive through IVF need more follow-up data beyond the pregnancy itself.

How a Specialized Clinic Approaches Adenomyosis in IVF Planning

A clinic built around individualized protocols treats an adenomyosis diagnosis as a starting point for investigation, not a fixed prognosis. That typically looks like:

A dedicated review of imaging using MUSA-based criteria, distinguishing direct from indirect markers before any protocol decision is made.
Multidisciplinary case review when findings are complex or a prior cycle failed unexpectedly.
A tailored pretreatment plan, medical suppression, surgical evaluation, or both, based on whether disease is diffuse or focal.
Individualized transfer timing rather than a fixed calendar, adjusted to how the patient responds to suppression.

Life IVF Center’s Precision IVF® approach emphasizes individualized planning based on imaging, symptoms, ovarian reserve, embryo factors, and prior treatment history. No clinic can guarantee a specific outcome, and published averages cannot predict an individual result.

A Manageable Factor, Not a Verdict

Adenomyosis can influence IVF planning, but it is rarely the only factor. Careful imaging review and individualized counseling can clarify how the diagnosis may affect a specific treatment plan without treating population averages as a personal forecast.

Shared decision-making matters here more than in most fertility conversations, precisely because so much depends on imaging detail rather than a single yes-or-no diagnosis. Bring the question checklist above into your next consultation, and don’t leave until you understand exactly where your case falls on the severity spectrum.

Getting Evidence-Based Adenomyosis Care Before Your Next IVF Cycle

If you have been diagnosed with adenomyosis, a focused consultation can review your imaging and discuss how the findings may affect IVF planning. Bring the full imaging report and any prior cycle records.

Bring prior imaging reports and IVF records to your consultation. Life IVF Center’s Precision IVF® approach uses those findings to guide an individualized discussion of suppression, transfer timing, surgical referral when appropriate, and fertility-preservation considerations. Results vary, and no treatment plan can guarantee an outcome.

Frequently Asked Questions

Can adenomyosis affect IVF success even with good-quality embryos?
Yes. A prospective study on donor oocyte transfers found reduced pregnancy rates and higher miscarriage even when embryo quality was controlled through donor eggs, pointing to the uterine environment itself as a driver of outcomes.

Does every adenomyosis diagnosis carry the same IVF risk?
No. Patients with direct ultrasound markers, myometrial cysts, hyperechogenic islands, face a substantially worse prognosis than those with only indirect markers like junctional zone irregularity, according to prospective cohort data.

How long does GnRHa suppression typically last before a frozen transfer?
Most protocols use 2 to 4 months of down-regulation, based on current clinical guidelines, though the exact duration should reflect individual response rather than a fixed calendar.

Is surgery ever recommended for adenomyosis before IVF?
Surgical options like adenomyomectomy are generally reserved for focal, well-defined lesions rather than diffuse disease, given the risk to uterine wall integrity and future pregnancy safety.

Should I get a second opinion if my adenomyosis report seems vague?
Yes, particularly if a prior IVF cycle failed without explanation. A second-opinion review of your imaging and treatment history can clarify whether adenomyosis severity was properly accounted for the first time.

This article is for general educational purposes only and is not a substitute for personalized medical advice, diagnosis, or treatment. Fertility care is individual; please consult a qualified healthcare professional about your circumstances. To discuss your options with our team, schedule a consultation with Life IVF Center.

Sources

The clearest picture of how adenomyosis affects IVF comes from a handful of high-quality sources, each contributing a different piece of the puzzle:

Uncategorized

Adenomyosis and IVF: How It Affects Success and What Helps

Key Takeaways

Table of Contents